Determination of the progression of prostate cancer using RT‑PCR method

Česká verzia

Authors: A. Zummerová ¹; M. Blaško ²; D. Böhmer ³; J. Filo ²; P. Kováč ¹; Vanda Repiská ³
Authors place of work: Súdnolekárske a patologicko‑anatomické pracovisko ÚDZS Bratislava, Slovenská republika, vedúci lekár MU Dr. Roman Kuruc ¹; Urologická klinika Lekárskej fakulty UK a UN akad. L. Dérera Bratislava, Slovenská republika, prednosta prof. MU Dr. Ján Breza, DrSc. ²; Ústav lekárskej biológie, genetiky a klinickej genetiky Lekárskej fakulty UK a UN Bratislava, Slovenská republika, prednosta doc. MUDr. Daniel Böhmer, PhD. ³
Published in the journal: Vnitř Lék 2010; 56(11): 1130-1137
Category: Original Contributions

Summary

The aim of our study
was to verify possible utilization of RT‑PCR method (Reverse Transcriptase-Polymerase Chain Reaction) as a diagnostic and prognostic modality of the progression of prostate cancer. This approach is commonly used for the detection of circulating carcinomatous cells in peripheral blood of patients with malignant breast tumors, and our ambition was to adopt this method for patients with prostate cancer. The contribution of this method consists in its ability to detect early stages of the dispersion of carcinomatous cells, so called micrometastases, in the peripheral circulation of patients. The estimation of the progression of the disease is especially important for the selection of appropriate therapy for individual patients. Using this method we analyzed 50 men: 28 patients with clinically localized or locally advanced prostate cancer, 7 patients with clinically proven metastases, 8 patients with benign prostatic hyperplasia, and 7 healthy young men.

Key words:
carcinoma of the prostate – RT‑PCR reaction – micrometastases – prostatic specific antigen – prostate specific membrane antigen

Zdroje

1. Fletcher CH. Histology of tumors. Vol. 1. Philadelphia: Churchill Livingstone Elsevier 2007: 755– 778.

2. Tanagho EA, McAninch JW. Smithova všeobecná urológia. Martin: Vydavateľstvo Osveta 2006: 392– 394.

3. Kliment J, Horňák M. Karcinóm prostaty. Martin: Vydavateľstvo Osveta 1999.

4. Chon CH, Lai FC, McNeal JE et al. Use of extended systematic sampling in patients with a prior negative prostate needle biopsy. J Urol 2002; 167: 2457– 2460.

5. Rubin E, Gorstein F, Rubin R et al. Rubin’s pathology: clinicopathologic foundations of medicine. 4th ed. Philadelphia: Lippincott Williams & Wilkins 2005: 921– 925.

6. Svačina S. Tumours of kidneys, urinary bladder and prostate in obesity and diabetes. Vnitř Lék 2008; 54: 464– 467.

7. Broďák M, Romzová M, Kosina J. Urologic surgery in diabetes. Vnitř Lék 2008; 54: 457– 463.

8. Egevad L. Recent trends in Gleason grading of prostate cancer: I. Pattern interpretation. Anal Quant Cytol Histol 2008; 30: 190– 198.

9. Leak B, Wei JT, Gabel M et al. Relevant patient and tumor considerations for early prostate cancer treatment. Semin Urol Oncol 2002; 20: 39– 44.

10. Lamb DS, Slaney D, Smart R et al. Prostate cancer: the new evidence base for diagnosis and treatment. Pathology 2007: 39: 537– 544.

11. Jung K, Henke W, Lein M et al. Polymerase chain reaction in the detection of micrometastases and circulating tumor cells. Cancer 1996; 78: 2445– 2448.

12. Haas CJ, Wagner T, Wawroschek F et al. Combined application of RT‑PCR and immunohistochemistry on paraffin embedded sentinel lymph nodes of prostate cancer patients. Pathol Res Pract 2005; 200: 763– 770.

13. Katz AE, Olsson CA, Raffo AJ et al. Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase – PCR assay. Urology 1994; 43: 765– 775.

14. Wood DP Jr, Banks ER, Humphreys S et al. Sensitivity of immunohistochemistry and polymerase chain reaction in detecting prostate cancer cells in bone marrow. J Histochem Cytochem 1994; 42: 505– 511.

15. Altimari A, Grigioni A, Benedettini E et al. Diagnostic role of circulating free plasma DNA detection in patients with localized prostate cancer. Am J Clin Pathol 2008; 129: 756– 762.

16. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106– 130.

17. Bartsch G, Khoury S, Murai M et al. Prostate Cancer. Paris: Health Publications 2003.

18. Choo R, DeBoer G, Klotz L et al. PSA doubling time of prostate carcinoma managed with watchful waiting observation alone. Int J Radiat Oncol Biol Phys 2001; 50: 615– 620.

19. Narita D, Raica M, Anghel A et al. Immunohistochemical localization of prostate- specific antigen in benign and malignant breast conditions. Rom J Morphol Embryol 2005; 46: 41– 45.

20. Moul JW. Prostate specific antigen only progression of prostate cancer. J Urol 2000; 163: 1632– 1642.

21. Ghossein RA, Scher HI, Gerald WL et al. Detecting of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications. J Clin Oncol 1995; 13: 1195– 1200.

22. Engstrom C. Hot flashes. Clin J Oncol Nurs 2006; 10: 533– 535.

23. Repiská V, Zummerová A, Mikloši M et al. Využitie metódy RT‑PCR pri detekcii cirkulujúcich mikrometastáz. Rozhl Chir 2003; 82: 95– 102.

24. Schmittgen TD, Teske S, Vessella RL et al. Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients. Int J Cancer 2003; 107: 323– 329.

25. Moreno JG, Croce CM, Fischer R et al. Detection of hematogenous micrometastasis in patients with prostate cancer. Cancer Res 1992; 52: 6110– 6112.

26. Repiská V, Mikloši M, Zummerová A et al. Detection of circulating tumor cells in patients with prostate cancer. Bratislava: Biologia 2005: 703– 709.